For emerging biotech companies, the right partnerships are pivotal to growth. Dr. Tony Sasse, Founder & Managing Director of Snoretox, shares how his team identified investors and collaborators who believed in their mission and understood their market. Learn how strategic alignment is helping Snoretox progress toward licensing and manufacturing deals that will bring their innovation to market.

A well-timed bridge investment can mean the difference between stalling and scaling. Dr. Asel Sartbaeva, CEO and co-founder of EnsiliTech, reflects on how family office support provided crucial bridge, enabled better deal terms, and positioned the company to close an oversubscribed £4.5 million round.

Machine learning is reshaping discovery science in Human Health and Organicin Scientific is proving its potential in animal health too. Mat Mitchell, Co-Founder and CTO, shares how Organicin Scientific’s machine-learning platform automates candidate selection to identify, evaluate, and commercialise novel antimicrobials for safe and sustainable use across the industry.

During the presentation, I’ll describe how innovation rarely follows a linear path, and how technology delays and regulatory change require decisions to be revisited after capital has already been deployed — with a focus on maintaining strategic intent and building value for investors.